Answers are grounded in this paper and cite their sources.
Computational analysis evaluates the antidiabetic potential of Diplazium esculentum in targeting key enzymes, indicating promising natural inhibition for diabetes management.
Objective: Diplazium esculentum (Retz.) Sw. is a dietary plant and possesses diverse biological properties, including potential antidiabetic effects. However, the antidiabetic potential of its young fronds remains unexplored. To bridge this gap, we conducted a computational analysis to assess their anti-diabetic activity by targeting key enzymes, α-amylase and α-glucosidase, which perform a fundamental role in the development of diabetes mellitus (DM). Materials and Methods: The ligands and target proteins associated with DM were obtained from PubChem and the Protein Data Bank, respectively. Drug-likeness and absorption, distribution, metabolism, excretion, and toxicity properties were assessed using MolSoft and the pkCSM repository for predictive modeling. This study investigated their interaction with key carbohydrate-hydrolysing enzymes involved in DM pathogenesis. Molecular docking was executed to appraise the binding energy of selected bioactive compounds. Results: Among the 11 docked phytochemicals, quercetin exhibited the highest binding energy (−294.64 kcal/mol) with α-amylase, forming three hydrogen bonds with key amino acid units. In addition, α-glucosidase docking results showed strong binding interaction with quercetin (−121.471 kcal/mol), forming three hydrogen bonds with two amino acids. Further investigation of quercetin, which exhibited the highest binding energy with α-amylase, was conducted using Schrödinger Maestro for molecular dynamics simulation at 500 ns. The results demonstrated improved stability, as indicated by root-mean-square fluctuation, root-mean-square deviation, and protein-ligand contact analyses, reinforcing its potential as a promising inhibitor of α-amylase. Conclusions: Bioactive compounds from D. esculentum , like quercetin, show promise as natural inhibitors for managing type 2 diabetes, warranting further research and development.
No takes yet. Share an insight, caveat, or question.
Bhattacharjee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: